A phase 3 study of acelarin in combination with cisplatin for biliary tract cancer is being discontinued at the recommendation of the study’s independent data monitoring committee, according to a press release from the agent’s manufacturer.
The decision follows a preplanned futility assessment performed at the first interim analysis of the NuTide:121 study.
The study evaluated acelarin (NUC-1031, NuCana) — a chemical modification of gemcitabine — plus cisplatin vs. standard-of-care gemcitabine plus cisplatin among patients with advanced biliary tract cancer.
The acelarin